This review highlights the efficacy and safety of combining lercanidipine and enalapril for the treatment of hypertension, particularly in patients with metabolic syndrome.
Answers are grounded in this paper and cite their sources.
Supports lercanidipine-enalapril combination in hypertension with metabolic syndrome; leaves open confirmation in prospective RCTs.
Data about the current approach to the choice of dual antihypertensive combinations in various clinical situations for treatment of hypertension are presented. Advantages and indications for the combination of an ACE inhibitor with a dihydropyridine calcium channel blocker are reviewed. Data from prospective studies on the efficacy and safety of combination of third generation calcium channel blocker lercanidipine with ACE inhibitor enalapril are presented.
No takes yet. Share an insight, caveat, or question.
Шилов et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: